Billiontoone Launches A Clinical Research Agreement With UCSD And...
healthcaretechoutlook

Billiontoone Launches A Clinical Research Agreement With UCSD And The Launch Of Oncology Liquid Biopsy Tools For Research Usage

Healthcare Tech Outlook | Thursday, September 01, 2022

BillionToOne has launched its study program with academic centers to further substantiate the data for these two goods after completing its internal investigation of the products on six different cancer kinds.

Fremont, CA: Leading biopharma and pharmaceutical businesses are concentrating on conducting virtual clinical trials and using innovative technology for oncology trials. The cancer treatment field has seen fierce rivalry, with companies vying for early product releases and adopting immunotherapies in conjunction with other targeted therapies. To strengthen the cancer pipeline, most top pharma and biopharma companies are concentrating on researching new mechanisms, such as immunological checkpoint inhibitors like BiTEs, antibody-drug conjugates (ADCs), and CTLA-4 inhibitors, PD-1 and PD-L1 inhibitors, and BiTEs.

Northstar Select and Northstar Response are the first cancer liquid biopsy solutions from BillionToOne, Inc.. This next-generation molecular diagnostics firm aims to provide powerful and accurate tests accessible to everybody. The products are now available for research at a few university cancer institutes.

Northstar Select is a robust somatic mutation profiling panel for pan-cancers. The panel provides an industry-leading detection limit for identifying actionable modifications by leveraging BillionToOne's patented molecular counting technique or Quantitative Counting Templates (QCTs). Northstar Response is a tissue-independent, methylation-based therapy response monitoring test. Using the molecular counting method, the assay delivers absolute quantification of methylation circulating tumor DNA (ctDNA) burden. When it becomes clinically available in Q1 2023, the assay will allow doctors to track patients' reactions to medicines, even in late-stage tumors where minimum residual disease (MRD) assays may be less informative or useful. BillionToOne published findings on their methylation test at this year's American Association for Cancer Research (AACR) Conference in April, demonstrating that it can identify minute variations in cell-free tumor DNA burden as tiny as 0.5 percent vs. 0.55 percent tumor burden.

BillionToOne has launched its study program with academic centers to further substantiate the data for these two goods after completing its internal investigation of the products on six different cancer kinds.

BillionToOne also issued that it has entered into a research collaboration agreement with the University of California, San Diego (UCSD). Northstar Select and Northstar Response will get tested on patients with advanced non-small-cell lung cancer (NSCLC).

BillionToOne is currently performing additional clinical trials with other academic cancer centers on various cancer types. The commercial versions of Northstar Select and Northstar Response for clinical use are projected to be available in Q1 2023.

Weekly Brief